Woven bone disease (Osteogenesis imperfecta type III) - Symptoms, Causes, Treatment & Prevention

```html

Overview

Woven bone disease is the lay‑term often used for the severe form of osteogenesis imperfecta (OI) type III. OI is a genetic connective‑tissue disorder characterized by bone that breaks easily, because the collagen that gives bone its strength is defective or insufficient. Type III is the second‑most severe form that is compatible with life; patients typically have marked bone deformities, short stature, and multiple fractures beginning in infancy.

• Who it affects: Both males and females; inheritance is usually autosomal‑dominant, but 30‑40 % arise from new (de‑novo) mutations.
• Prevalence: OI overall occurs in about 1 in 15,000–20,000 live births. Type III accounts for roughly 10‑15 % of all OI cases, giving an estimated worldwide prevalence of 1‑2 per 150,000 people.<sup>1</sup>
• Terminology note: “Woven bone disease” refers to the abnormal rapid deposition of immature, “woven” bone that is histologically disorganized, leading to fragility and deformity.

Symptoms

Symptoms of OI type III are present from birth or early infancy and tend to worsen with growth. The following list captures the full spectrum, though not every individual experiences every item.

Skeletal Manifestations

• Multiple fractures: Often occurring with minimal or no trauma; fractures can be present at birth (in‑utero fractures) and continue throughout life.
• Bone deformities: Bowing of long bones, especially the femur and tibia; vertebral compression leading to kyphoscoliosis.
• Short stature: Adult height typically 3‑4 ft (90‑120 cm) without growth‑enhancing therapy.
• Wormian bones: Extra small bones within the sutures of the skull, visible on X‑ray.
• Blue sclerae: A bluish tinge of the whites of the eyes due to visible underlying choroidal veins.
• Dental problems (Dentinogenesis imperfecta): Opalescent, fragile teeth that chip easily.
• Hearing loss: Conductive or mixed loss begins in adolescence or early adulthood.

Soft‑Tissue & Other Systemic Features

• Joint laxity & contractures: Hypermobile shoulders/hips but often become stiff due to repeated fractures and surgery.
• Muscle weakness: Secondary to limited mobility and chronic pain.
• Skin: Easy bruising; thin translucent skin overlying bone in some areas.
• Cardiovascular: Rarely, valvular disease or aortic root dilation.
• Respiratory complications: Reduced chest wall compliance can lead to restrictive lung disease, especially in severe cases.

Causes and Risk Factors

OI type III is caused primarily by mutations that affect the quality or amount of type I collagen, the main structural protein in bone, skin, and tendon.

Genetic Causes

• COL1A1 and COL1A2 genes: Mutations in either of these two genes account for >90 % of OI cases. Type III usually involves missense mutations that produce a structurally abnormal collagen chain.
• Other genes (rare): CRTAP, P3H1, SERPINH1, IFITM5, and others involved in collagen post‑translational processing can produce a type III‑like phenotype.

Inheritance Patterns

• Autosomal‑dominant: One parent carries the pathogenic variant; each child has a 50 % chance of inheriting it.
• De‑novo mutation: In ~30‑40 % of cases, the mutation appears for the first time in the affected child; parents are not carriers.
• Autosomal‑recessive (rare): Both parents carry a mutation in the same non‑COL1A gene.

Risk Factors for Severe Outcomes

• Early onset of fractures (in utero or neonatal)
• Severe vertebral compression leading to thoracic insufficiency
• Lack of early multidisciplinary care (orthopedic, endocrinology, physiotherapy)
• Coexisting medical conditions such as severe scoliosis or respiratory disease

Diagnosis

Diagnosis is clinical, supported by imaging and genetic testing. Early recognition is essential to start bisphosphonate therapy and to prevent complications.

Clinical Evaluation

• Detailed family history and physical examination (blue sclerae, dentinogenesis imperfecta, limb deformities).
• Assessment of growth parameters and functional status.

Imaging Studies

• Radiographs: Show multiple healed fractures, bowing of long bones, vertebral compression, and wormian bones.
• Bone mineral density (BMD) testing (DXA): Quantifies low bone mass; used to monitor treatment response.
• CT/MRI: Reserved for complex spinal deformities or surgical planning.

Laboratory & Genetic Testing

• Serum calcium, phosphate, alkaline phosphatase, vitamin D: To rule out secondary metabolic bone disease.
• Genetic panel: Targeted sequencing of COL1A1, COL1A2, and other OI‑related genes. Whole‑exome sequencing is increasingly used when panel results are negative.
• Genetic testing confirms the diagnosis in >95 % of cases and guides counseling.

Treatment Options

There is no cure, but a combination of pharmacologic, surgical, and supportive measures can dramatically improve quality of life and reduce fracture frequency.

Pharmacologic Therapy

• Bisphosphonates (first‑line): Intravenous pamidronate or zoledronic acid improves BMD and reduces fracture rate in children. Typical regimen: pamidronate 1 mg/kg every 3‑4 weeks for 6‑12 months, then spaced out.
• Denosumab: RANK‑L inhibitor; data in OI are emerging, may be considered when bisphosphonates are contraindicated.
• Growth hormone: In selected short‑stature patients, recombinant GH can add 1–2 cm/year of height when combined with bisphosphonates.
• Analgesics: Acetaminophen or NSAIDs for acute pain; opioids only for severe breakthrough pain under supervision.
• Supplements: Calcium 1,000–1,300 mg/day and vitamin D 800–1,000 IU/day to ensure adequate bone mineralization.

Surgical Interventions

• Rodding & Intramedullary Stabilization: Placement of telescopic rods (e.g., Fassier‑Duval) allows the bone to grow while preventing deformity and reducing fracture frequency.
• Spinal Fusion: For severe scoliosis or thoracic insufficiency syndrome.
• Orthopedic realignment: Osteotomies to correct bowing, often combined with rod insertion.
• Dental restoration: Crowns and protective splints for fragile teeth.

Rehabilitation & Lifestyle

• Physical therapy: Early, gentle weight‑bearing and muscle‑strengthening exercises improve bone mass and motor skills.
• Occupational therapy: Adaptive equipment (wheelchairs, standing frames, protective padding) to promote independence.
• Assistive devices: Custom orthotics, braces, and low‑impact activities (swimming, stationary cycling).
• Nutrition: High‑protein diet, adequate calories, and avoidance of smoking/alcohol, which impair bone health.

Living with Woven Bone Disease (Osteogenesis Imperfecta Type III)

Managing day‑to‑day life requires a team approach and proactive planning.

Practical Tips

• Home safety: Install grab bars, soft‑flooring, and low‑height furniture. Keep pathways clear of clutter.
• Clothing: Loose, non‑restrictive garments; avoid tight belts that could cause pressure fractures.
• Transportation: Use a wheelchair or scooter for longer distances; secure the seat belt properly to avoid impact during sudden stops.
• School & work: Request accommodations—extra time for moving between classes, a schedule that avoids heavy lifting, and ergonomic workstations.
• Weight‑bearing exercise: Under physical‑therapy guidance, engage in 20‑30 minutes of low‑impact activity most days to stimulate bone formation.
• Regular follow‑up: At least biannual visits with a pediatric/endocrine specialist, annual orthopedic assessment, and dental check‑ups every 6 months.

Psychosocial Support

• Connect with OI support groups (e.g., International Osteogenesis Imperfecta Foundation).
• Consider counseling to address anxiety, body image concerns, and coping strategies.
• Family education about safe handling and emergency procedures is essential.

Prevention

Because OI type III is genetic, primary prevention of the disease itself is not possible, but several measures can reduce the risk of fractures and complications.

• Genetic counseling: Recommended for families with a known mutation; prenatal testing or pre‑implantation genetic diagnosis can be discussed.
• Early treatment initiation: Starting bisphosphonate therapy within the first year of life is associated with fewer long‑term fractures.
• Environmental modifications: Fall‑proofing homes and schools reduces accidental trauma.
• Optimized nutrition & vitamin D status: Ensures the bone‑building capacity of any pharmacologic therapy.
• Regular monitoring: Prompt detection of new scoliosis or thoracic insufficiency allows earlier surgical intervention.

Complications

If left inadequately managed, OI type III can lead to serious health issues.

• Progressive scoliosis or kyphosis: May cause chronic pain, restrictive lung disease, and reduced stature.
• Thoracic insufficiency syndrome: Inability of the chest to expand adequately, leading to respiratory failure.
• Hearing loss: Conductive hearing loss affecting communication and quality of life.
• Dental loss: Frequent tooth fracture or loss, requiring extensive prosthetic rehabilitation.
• Chronic pain & depression: Repeated fractures and limited mobility can contribute to mental health disorders.
• Cardiovascular strain: Severe scoliosis may compress the heart or great vessels.
• Fracture‑related complications: Malunion, non‑union, or acute compartment syndrome after a high‑energy injury.

When to Seek Emergency Care

---

**References**

1. Mayo Clinic. Osteogenesis imperfecta – Symptoms and causes. https://www.mayoclinic.org
2. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Osteogenesis Imperfecta. https://www.niams.nih.gov
3. American Academy of Orthopaedic Surgeons. Management of Osteogenesis Imperfecta. https://www.aaos.org
4. World Health Organization. Genetic testing guidelines. https://www.who.int
5. International Osteogenesis Imperfecta Foundation. Clinical Care Guidelines (2023 update). https://www.ioi.org

```